Molecular diagnosis in cannabis allergy

Armentia, Alicia; Herrero, M.; Blanca, M.; Rihs, Hans‐Peter; Postigo, Idoia; Martínez-Quesada, Jorge

doi:10.1016/j.jaip.2014.01.015

Cited by 26 publications

(17 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 10-kDa IgE binding band was already described in other reports (10,24,25) and corresponds to Can s 3, the nonspecific lipid protein (ns-LTP) of C. sativa (10) that belongs to the pathogenesis-related proteins (PR)-14 group (26). Sensitization to the ns-LTP Can s 3 was observed in 124 of 130 patients (95.3%) with a primary cannabis allergy in a Spanish study (27). In our own casecontrol study, sensitization to ns-LTP was demonstrable in 10 of 12 (83%) patients with cannabis-related food allergies (8).…”

Section: Allergenic Componentsmentioning

confidence: 58%

“…CRD not only allows one to discriminate between genuine allergy and cross-reactivity, but also enables to establish individual sensitization profiles, which can be highly relevant in food allergy. In a study by Armentia et al (27), sIgE antibodies against purified cannabis ns-LTP were demonstrable in over 95% of the patients with a primary cannabis allergy. Recently, Rihs et al (34) succeeded to clone Can s 3 from C. sativa L ssp sativa cv Kompolti and to study its IgE binding properties.…”

Section: Diagnosismentioning

confidence: 94%

“…Presently, sensitization and allergy to cannabis is almost exclusively studied or documented by prick-prick skin testing. Prick-prick skin tests use a broad variety of raw materials such as macerated C. sativa leaves, buds and flowers (5,8,10,14,15,17,18,22,24,27,(30)(31)(32)37). Needless to say that this approach is virtually impossible to standardize, mainly because of unpredictable variations in composition and potential contaminations with other allergens of the raw material.…”

Section: Diagnosismentioning

confidence: 99%

See 2 more Smart Citations

Cannabis sativaallergy: looking through the fog

Decuyper

Gasse

Cop

et al. 2016

Allergy

View full text Add to dashboard Cite

IgE-mediated Cannabis (C. sativa, marihuana) allergy seems to be on the rise. Both active and passive exposure to cannabis allergens may trigger a C. sativa sensitization and/or allergy. The clinical presentation of a C. sativa allergy varies from mild to life-threatening reactions and often seems to depend on the route of exposure. In addition, sensitization to cannabis allergens can result in various cross-allergies, mostly for plant foods. This clinical entity, designated as the 'cannabis-fruit/vegetable syndrome', might also imply cross-reactivity with tobacco, natural latex and plant-food-derived alcoholic beverages. Hitherto, these crossallergies are predominantly reported in Europe and appear mainly to rely upon cross-reactivity between nonspecific lipid transfer proteins or thaumatin-like proteins present in C. sativa and their homologues, ubiquitously distributed throughout plant kingdom. At present, diagnosis of cannabis-related allergies predominantly rests upon a thorough history completed with skin testing using native extracts from crushed buds and leaves. However, quantification of specific IgE antibodies and basophil activation tests can also be helpful to establish correct diagnosis. In the absence of a cure, treatment comprises absolute avoidance measures. Whether avoidance of further use will halt the extension of related cross-allergies remains uncertain.Cannabis sativa (C. sativa) is an annual, dioecious and anemophilous flowering plant (order: Rosales, family Cannabaceae) that is native to central and southern Asia and the Caucasian region. Different preparations [dried flowering tops, hashish, hashish oil] are obtained from cannabis varieties containing elevated levels of cannabinoids, especially delta-9-tetrahydrocannabinol (THC), several of them being more or less potent psychoactive substances. Although, today, cannabis use is still illegal in most countries, it is widespread for its relaxing and euphoric effects. Furthermore, worldwide the illegal status of the drug has gained more and more resistance recently, resulting in legalization of both sale and possession of marijuana in Colorado, Alaska, Oregan and Washington, for example, both for medicinal and recreational use (1). Different European countries are debating the legalization of cannabis as well. While consumption of cannabis has been legal under certain conditions for a while

show abstract

Section: Allergenic Componentsmentioning

confidence: 58%

Section: Diagnosismentioning

confidence: 94%

Section: Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Cannabis sativaallergy: looking through the fog

Decuyper

Gasse

Cop

et al. 2016

Allergy

View full text Add to dashboard Cite

show abstract

“…The 10-kDa IgE-binding band was already described in other reports (de Larramendi et al 2008;Gamboa et al 2007;Tanaka et al 1998) and most likely corresponds to Can s 3, the ns-LTP of C. sativa (Gamboa et al 2007) that belongs to the pathogenesis-related proteins (PR)-14 group (Van Loon 1999). In a study by Armentia et al (2014), sensitization to the purified cannabis ns-LTP was observed in 124 out of 130 patients (95.3 %) with a primary cannabis allergy.…”

Section: Cannabis Allergensmentioning

confidence: 99%

“…CRD not only allows one to discriminate between genuine allergy and cross-reactivity, but also enables to establish individual sensitization profiles which can be highly relevant in food allergy (Faber et al 2014). In a study by Armentia et al (2014), sIgE antibodies against purified cannabis ns-LTP were demonstrable in over 95 % of the patients with a primary cannabis allergy. Recently, Rihs et al (2014) succeeded to clone Can s 3 from C. sativa L ssp sativa cv Kompolti and to study its IgE-binding properties.…”

Section: Diagnosismentioning

confidence: 99%

Cannabis Allergy: What do We Know Anno 2015

Decuyper

Ryckebosch

Gasse

et al. 2015

Arch. Immunol. Ther. Exp.

View full text Add to dashboard Cite

For about a decade, IgE-mediated cannabis (marihuana) allergy seems to be on the rise. Both active and passive exposure to cannabis allergens may lead to a cannabis sensitization and/or allergy. The clinical manifestations of a cannabis allergy can vary from mild to lifethreatening reactions, often depending on the route of exposure. In addition, sensitization to cannabis allergens can trigger various secondary cross-allergies, mostly for plant-derived food. This clinical entity, which we have designated as the ''cannabis-fruit/vegetable syndrome'' might also imply cross-reactivity with tobacco, latex and plant-food derived alcoholic beverages. These secondary cross-allergies are mainly described in Europe and appear to result from cross-reactivity between non-specific lipid transfer proteins or thaumatin-like proteins present in Cannabis sativa and their homologues that are ubiquitously distributed throughout plant kingdom. At present, diagnosis of cannabis-related allergies rests upon a thorough history completed with skin testing using native extracts from buds and leaves. However, quantification of specific IgE antibodies and basophil activation tests can also be helpful to establish correct diagnosis. In the absence of a cure, treatment comprises absolute avoidance measures including a stop of any further cannabis (ab)use.

show abstract

Synthetic Cannabinoid Receptor Agonists

Monte¹

2017

Critical Care Toxicology

View full text Add to dashboard Cite

Molecular diagnosis in cannabis allergy

Cited by 26 publications

References 7 publications

Cannabis sativaallergy: looking through the fog

Cannabis sativaallergy: looking through the fog

Cannabis Allergy: What do We Know Anno 2015

Synthetic Cannabinoid Receptor Agonists

Contact Info

Product

Resources

About